Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 3
1958 3
1959 1
1960 4
1962 1
1964 1
1965 3
1966 4
1967 2
1968 2
1969 3
1970 10
1971 7
1972 9
1973 10
1974 6
1975 11
1976 7
1977 16
1978 8
1979 11
1980 6
1981 16
1982 10
1983 15
1984 18
1985 17
1986 11
1987 19
1988 16
1989 13
1990 24
1991 31
1992 19
1993 29
1994 32
1995 28
1996 29
1997 29
1998 41
1999 48
2000 53
2001 48
2002 60
2003 62
2004 60
2005 75
2006 81
2007 75
2008 92
2009 100
2010 139
2011 122
2012 159
2013 146
2014 134
2015 187
2016 182
2017 155
2018 194
2019 223
2020 274
2021 217
Text availability
Article attribute
Article type
Publication date

Search Results

3,029 results
Results by year
Filters applied: . Clear all
Page 1
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Chari A, et al. Among authors: shah j. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. N Engl J Med. 2019. PMID: 31433920 Clinical Trial.
Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review.
Coca-Pelaz A, Shah JP, Hernandez-Prera JC, Ghossein RA, Rodrigo JP, Hartl DM, Olsen KD, Shaha AR, Zafereo M, Suarez C, Nixon IJ, Randolph GW, Mäkitie AA, Kowalski LP, Vander Poorten V, Sanabria A, Guntinas-Lichius O, Simo R, Zbären P, Angelos P, Khafif A, Rinaldo A, Ferlito A. Coca-Pelaz A, et al. Among authors: shah jp. Adv Ther. 2020 Jul;37(7):3112-3128. doi: 10.1007/s12325-020-01391-1. Epub 2020 Jun 1. Adv Ther. 2020. PMID: 32488657 Free PMC article. Review.
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, Bruce JY, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Galloway T, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco JW, Rodriguez CP, Shah JP, Weber RS, Weinstein G, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. Pfister DG, et al. Among authors: shah jp. J Natl Compr Canc Netw. 2020 Jul;18(7):873-898. doi: 10.6004/jnccn.2020.0031. J Natl Compr Canc Netw. 2020. PMID: 32634781
Selinexor for the treatment of multiple myeloma.
Podar K, Shah J, Chari A, Richardson PG, Jagannath S. Podar K, et al. Among authors: shah j. Expert Opin Pharmacother. 2020 Mar;21(4):399-408. doi: 10.1080/14656566.2019.1707184. Epub 2020 Jan 19. Expert Opin Pharmacother. 2020. PMID: 31957504 Review.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD Jr, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S. Grosicki S, et al. Among authors: shah j. Lancet. 2020 Nov 14;396(10262):1563-1573. doi: 10.1016/S0140-6736(20)32292-3. Lancet. 2020. PMID: 33189178 Clinical Trial.
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA. Kalakonda N, et al. Among authors: shah j. Lancet Haematol. 2020 Jul;7(7):e511-e522. doi: 10.1016/S2352-3026(20)30120-4. Lancet Haematol. 2020. PMID: 32589977 Free article. Clinical Trial.
Elective neck dissection in oral squamous cell carcinoma: Past, present and future.
de Bree R, Takes RP, Shah JP, Hamoir M, Kowalski LP, Robbins KT, Rodrigo JP, Sanabria A, Medina JE, Rinaldo A, Shaha AR, Silver C, Suárez C, Bernal-Sprekelsen M, Ferlito A. de Bree R, et al. Among authors: shah jp. Oral Oncol. 2019 Mar;90:87-93. doi: 10.1016/j.oraloncology.2019.01.016. Epub 2019 Feb 10. Oral Oncol. 2019. PMID: 30846183 Free article. Review.
3,029 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page